RADIOThERAPy OF PROSTATE CANCER: PRIMARY RADIOThERAPy AND RADIOThERAPy IN DISEASE RELAPSE

Katarina Antunac

University Hospital for Tumors, Sestre milosrdnice University Hospital Center

SUMMARY – Radiotherapy presents one of the essential modes of treatment in patients with prostate cancer at almost any stage of the disease. It can be delivered as external beam radiotherapy, as brachytherapy or two methods combined. Higher radiation doses are proven to be more effective than low doses and moderate hypofractionation with doses up to 3.4 Gy per fraction is proven equivalent to standard fractionation using 1.8–2 Gy per fraction. Stereotactic body radiotherapy (SBRT) with doses from 3.4 to 7.25 Gy per fraction presents valuable option in certain subgroups of patients. In case of local regional disease relapse, radiotherapy is used in curative setting.

Key words: prostate cancer, radiotherapy, brachytherapy, hypofractionation, stereotactic body radiotherapy, salvage radiotherapy

Introduction

Radiotherapy in prostate cancer is undoubtedly efficacious treatment. In last decades a number of clinical trials exploring different radiotherapy modalities and schedules regarding dose and fractionation have been published. Nevertheless, due to methodological limits, it can be quite difficult to compare the results of various trials. In 1985 prostate specific antigen (PSA) was introduced. That has caused a significant downward risk migration over time, which had the impact on treatment (1). In 2016 International Society of Urological Pathology (iSUP) published consensus on contemporary grading and new prostate cancer grading system was introduced as a validated alternative to the Gleason score. That led to further risk group stratification (2, 3). Heterogeneity of used endpoints also contributes to methodological limits: overall survival, cancer specific survival, clinical relapse, biochemical relapse, not to mention various definitions of biochemical relapse. All those limits make interpretation and comparison of results of reported clinical trials, as well as their implementation in the current practice quite challenging.

The aim of this article is to present landmark trials that led to change of practice regarding the dose of radiotherapy, hypofractionation, use of stereotactic radiotherapy, brachytherapy and the role of radiotherapy in locoregional disease relapse.

Methods

A literature search of MEDLINE via PubMed was performed for the following terms: “RT”, “radiation”, “irradiation”, “prostatic neoplasms/RT”, “brachytherapy”, “dose fractionation”, “skeletal neoplasms/RT”, “salvage radiotherapy”.

Results

Dose escalation

A number of clinical trials have addressed the role of dose escalation on the disease outcome and the toxicity of higher doses.

One of the first dose escalation trials was Medical Research Council (MRC) 01 trial. It randomized 843 patients whose prostate cancer was staged as T1b–T3a N0 M0 and PSA level was less than 50 mg/mL, to
receive either 64 Gy in 32 fractions, conformal radiotherapy, which was standard dose at the time (control group), or 74 Gy in 37 fractions (dose-escalated group). Three to six months before the beginning of irradiation, neoadjuvant androgen deprivation therapy started, and was continued until the end of radiation treatment. After a median follow up of 10 years, biochemical progression-free survival was 43% in the control group and 55% in the dose-escalated group (p = 0.0003). No difference was observed in overall survival; it was 71% in each group. Patients allocated to dose-escalated group had an increased rate of both acute and late toxicity (4).

GETUG06 trial randomized 306 patients with localized prostate cancer to receive 70 Gy or 80 Gy on prostate, without androgen deprivation. After 61 months of follow up, the 5-year biochemical relapse rate was 32% and 23.5%, respectively (p = 0.09) using Phoenix definition (nadir PSA plus 2 ng/ml). Better biochemical outcome for the higher dose group was observed in patients whose initial PSA levels were above 15 ng/ml. No difference in mortality between the two treatment approaches was noticed. Higher dose group patients had significantly more grade 2 urinary toxicity (17.5% compared to 10% at 70 Gy, p = 0.046) and bladder toxicity (p = 0.039). No significant differences in grade 2 or greater rectal toxicity nor in quality of life were reported among the patient groups (5).

In the Dutch trial, in 664 patients with T1b-T4N0 prostate cancer doses of 78 Gy and 68 Gy were compared. Use of androgen deprivation therapy was allowed. Biochemical and/or clinical failure (BCF) was trial’s primary endpoint. Both ASTRO (American Society for Therapeutic Radiology and Oncology) guidelines (3 consecutive PSA rises) and Phoenix definition (nadir PSA plus 2 ng/ml) were used to define it. After 110 months of follow up, BCF and local failure (LF) rates were significantly lower in the group of patients receiving 78 Gy (p < 0.05). However, no differences in clinical failure (CF), death from prostate cancer (PCD), and overall survival (OS) were observed (6, 7).

In the trial published by Kuban et al., 301 T1b-T3 prostate cancer patients were randomized to receive 70 Gy or 78 Gy. Median follow up was 9 years. Higher biochemical and clinical failure rates, as well as higher risk of dying of prostate cancer, were observed in patients with high-risk disease or with pre-treatment PSA level > 10 ng/ml, if irradiated to 70 Gy. If treated with 70 Gy, patients that were less than 70 years old at treatment died three times more frequently of prostate cancer than of other causes. In this age group, patients were more likely to die from other causes if irradiated with 78 Gy. Patients that were 70 or older died of both prostate cancer and of other causes equally, if treated with 70 Gy. In this age group, not a single patient receiving 78 Gy died of prostate cancer. In conclusion, in patients with high-risk disease moderate dose escalation using radiation dose of 78 Gy offers better biochemical and clinical control and decreases death from prostate cancer. That also applies to patients whose pre-treatment PSA levels were above 10 ng/ml (8).

Total of 1532 prostate cancer patients were enrolled in NRG Oncology RTOG 0126 Randomized Clinical Trial. Patients’ characteristics were the following: clinical stage T1b to T2b, Gleason score (GS) 2 to 6 with prostate specific antigen (PSA) values between 10–20 ng/ml; or GS 7 with PSA levels less than 15 ng/ml. Patients were randomized to receive 79.2 Gy in 44 daily fractions of 1.8 Gy or 70.2 Gy in 39 daily fractions of 1.8 Gy. Three-dimensional conformal radiation therapy (3D CRT) or intensity-modulated radiation therapy (IMRT) were used as radiation techniques. Study endpoints were overall survival (OS), biochemical failure (BF, Phoenix or ASTRO definition) and frequency of acute and late radiation treatment toxic effects. Acute side effects were those occurring less than 90 days of the start of the treatment. In case side effects occurred more than 90 days from the start of the treatment, they were defined as late side effects.

After a median follow up of 8.4 years, there was no difference in OS between the groups; OS rates were 76% in group of patients receiving 79.2 Gy and 75% in the group of patients receiving 70.2 Gy (p = 0.98). Distant metastases occurred in 4% and 6%, respectively (p = 0.05). Biochemical failure, as per ASTRO definition, after 5 and 8 years of follow up, occurred in 40% and 47% of patients allocated to 70.2-Gy arm. In patients receiving 79.2 Gy, those figures were 25% and 31%, respectively (p < 0.001). Salvage therapy, namely androgen deprivation, cryosurgery or brachytherapy, was significantly more often used in patients in the 70.2-Gy arm (p < 0.001). Frequency of acute gastrointestinal (GI) and genitourinary (GU) toxicity was not significantly different between the arms. However, af-
ter 5 years of follow up, late grade 2 or greater GI and/or GU toxicity was significantly more often in 79.2-Gy group (9).

Two meta-analyses tried to determine the difference in outcomes of patients with localized prostate cancer regarding radiotherapy dose; namely is high-dose radiotherapy (HDRT) more efficient than conventional-dose radiotherapy (CDRT).

Meta-analysis by Viani et al. quantified if the total radiotherapy dose has an impact on biochemical control of the disease. It analyzed the data from 2812 patients enrolled in seven randomized controlled trials. If patients were treated with high doses, biochemical failure incidences were significantly reduced (p < 0.0001). That benefit was consistent across the risk groups. No difference has been observed between the treatment groups regarding mortality rate (p = 0.38) and specific prostate cancer mortality rate (p = 0.45). Late grade >2 gastrointestinal toxicity was more frequent after HDRT. According to the authors, these results suggest that HDRT provides a better therapeutic option for patients in all risk groups - low, intermediate and high (10).

Zan et al. in their meta-analysis evaluated 6 randomized controlled trials of long-term follow-ups to assess efficacy and toxicity of HDRT and CDRT. Trials included 2,822 patients. In terms of 10-year efficacy, HDRT was associated with a significant reduction of biochemical failure rates: 34.0% vs. 24.7%, p < 0.00001, but no difference was observed in overall survival (73.4% vs. 74.3% p = 0.64) and prostate cancer specific survival (PCSS; 90.7% vs. 91.6%, p = 0.47). Decrease of biochemical failure at 10 years was consistent in all trials, regardless of androgen deprivation therapy. Patients treated with HDRT had a significantly later grade 2 or higher (G ≥ 2) GI (28.0% vs. 18.6%, p < 0.00001) and GU toxicity (22.6% vs. 19.5%, p = 0.04). There was no significant difference in quality of life between HDRT and CDRT (p > 0.05). Since the advantage in biochemical control did not translate into an improvement in OS and PCSS and HDRT was connected with worse late toxicity outcomes, these authors are more cautious and suggest that HDRT should be discreetly used in the treatment of patients with prostate cancer (11).

Kalbasi and al. analyzed the data of 42,481 prostate cancer patients from National Cancer Data Base (NCDB). 12,229 patients had a low risk, 16,714 intermediate risk and 13,538 high risk disease. They underwent radiotherapy in the period between 2004 and 2006. Threshold for distinction between the groups was 75.6 Gy; therefore, doses between 68.4 and 75.6 Gy were referred as standard dose and those between 75.6 and 90 Gy as escalated dose.

Patients with intermediate and high-risk prostate cancer had a better OS if treated with higher doses (p < 0.001). However, this benefit has not been shown for low risk prostate cancer patients (p = 0.54). In intermediate risk group a 7.8% reduction of death risk has been observed with every 2 Gy dose increment. In high risk group death risk reduction per every 2 Gy dose increment was 6.3% (12).

Trials are summarized in Table 1. (13)

**Hypofractionated radiation therapy—hypofractionation**

Term standard fractionation stands for the delivery of radiotherapy in daily doses (fractions) of 1.8 -2 Gy. In case daily doses higher than 2 Gy are being used, that kind of radiation treatment is referred to as hypofractionated radiation therapy or hypofractionation. The α/β ratio is a radiobiological parameter explaining how normal and cancer tissues would respond to different radiation schedules. According to literature data, α/β ratio of prostate cancer is assumed to be about 1.5; therefore, sensitivity of prostate cancer on fraction size is to be expected. Hypofractionation could be moderate with daily fractions between 2.1 and 3.4 Gy or extreme, in case daily fractions higher than 3.4 Gy are used.

Besides expected clinical benefit, hypofractionated radiation treatment is given in lower number of radiation sessions. That makes overall treatment time shorter, which is more convenient for both patient and staff.

**Moderate hypofractionation**

A number of randomized clinical trials evaluated use of moderate hypofractionation (MH) in prostate cancer patients. Basically, short biochemical disease control between treatment arms was similar. However, due to short follow up, long-term effects on organs at risk, namely bowel and bladder, are not yet completely recognized.

First randomized studies were undertaken in Australia and Canada. The rationale of the hypofraction-
Table 1 Dose escalation trials in localized prostate cancer (13)

| Trial                           | No of patients | Stage                        | Radiation dose                  | Follow-up | Outcome                                                                 | Results                                                                 |
|---------------------------------|----------------|------------------------------|---------------------------------|-----------|--------------------------------------------------------------------------|-------------------------------------------------------------------------|
| MRC RT01 Deaneley et al.        | 843            | T1b-T3a N0M0, PSA<50 ng/ml neoadj. HT | 64 vs. 74 Gy                    | median 10 years | biochemical progression free survival (BFS), overall survival (OS)       | BFS 43% 64Gy, 55% 74Gy (p= 0.0003), OS 71% both groups (p= 0.96) |
| GETUG 06 Beckendorf et al. Int J Radiat Oncol Biol Phys 2011 | 306            | T1b-3a, N0, M0, PSA<50 ng/ml | 70 vs. 80 Gy                    | median 61 month | ASTRO biochemical failure (BCF)                                         | BF 39% 70Gy, 28% 80Gy                                                   |
| Dutch trial Heemsbergen et al. Radiother Oncol 2014 | 664            | T1b-T4 164 patients with neoadjuvant HT | 68 vs. 78 Gy                    | median 110 months | biochemical (Phoenix definition) and clinical failure free (FFF)        | FFF 43% 68Gy, 49% 78 Gy (p= 0.045)                                    |
| MD Anderson Kuban et al. Int J Radiat Oncol Biol Phys, 2011 | 301            | T1-3, N0, M0, PSA 10 ng/ml vs. PSA >10 ng/ml | 70 vs. 78 Gy                    | median 9 years | disease specific mortality (DSM) vs. other cause of death               | high risk: (PSA> 10): DSM 16% 70Gy, 4% 78Gy (p=0.05) higher risk DSM 15% 70Gy, 2% 78. Gy (p=0.03) |
| RTOG 0126, Michalsky et al, JAMA Oncol. 2018 | 1,532           | T1b-T2b ISUP grade 1 + PSA 10-20 ng/ml or ISUP grade 2/3 + PSA < 15 ng/ml | 70.2 vs. 79.2 Gy | 100 mo | overall survival (OS) distant metastases (DM) biochemical failure (BCF, ASTRO definition) | 75% OS at 70.2 Gy 76% OS at 79.2 Gy 6% DM at 70.2 Gy 4% DM at 79.2 Gy (p = 0.05) 47% BCF at 70.2 Gy 31% BCF at 79.2 Gy (p < 0.001; Phoenix, p < 0.001) |
| retrospective NCDB trial Kabasi et al, JAMA Oncol 2015 | 12 229          | low risk, 22% HT intermediate risk, 49% HT high risk, 77% HT | <75.6 vs > 75.6 Gy              | median 85-86 months | overall survival (OS)                                                   | HR 0.98, for dose escalation (p= 0.54) HR 0.84 for dose escalation (p<0.001) HR 0.82 for dose escalation (p< 0.001) |
|                                |                |                              |                                 |           |                                                                           |                                                                         |

ation, however, was not prostate cancer α/β ratio but the convenience of shorter overall treatment time. Due to countries’ size, in both Australia and Canada patients had to travel large distances in order to get radiotherapy (14).

In NCI Canada trial with a reported median follow up of 5.7 years, 936 patients were enrolled. Prostate cancer was staged as clinically T1-T2 and PSA levels had to be below 40 ng/ml. Patients were randomized to receive hypofractionated radiotherapy (52.5 Gy in daily fractions of 2.62 Gy) or conventionally fractionated radiotherapy (66 Gy in 33 daily fractions of 2 Gy). No concomitant antiandrogen therapy was used. Biochemical or clinical failure (BCF) was set...
as the study’s primary outcome. At 5 years, the BCF probability in the short arm was 59.95% and in the long arm 52.95%. Those data gave the advantage to the long arm approach. There was no difference between the arms regarding overall survival or 2-year post-radiotherapy biopsy. When compared to the long arm, patients in the short arm had a higher frequency of acute toxicity (11.4% vs. 7%). No difference was detected between the arms in terms of the late toxicity (3.2%). It should be stressed that doses used in both arms of the trial are lower than those being used nowadays (15).

In Australian trial 217 patients were randomized to either hypofractionated or conventionally fractionated radiation treatment. Patients in hypofractionated arm received 55 Gy during 4 weeks in 20 daily fractions and patients in the control arm received 64 Gy in 32 daily fractions; their overall treatment time was 6.5 weeks. It is to notice that 156 patients received two-dimensional radiotherapy and for RT planning two-dimensional computed tomography method was used. After a median follow up of 90 months, biochemical relapse, which was defined as nadir PSA +2 ng/ml occurred in 36 patients in the hypofractionated group and in 49 patients in the control group. Therefore, 90-month biochemical relapse free survival turned out to be significantly better with the hypofractionated schedule (53% vs. 34%). There was no difference in overall survival between the arms. Genitourinary and gastrointestinal toxicity was similar between the schedules and it persisted 60 months upon radiotherapy (16).

These first hypofractionation trials undoubtedly demonstrated feasibility of the concept, but due to applied radiotherapy techniques and doses that no longer present standard of care, their efficacy and toxicity data should be taken into consideration cautiously.

Three modern, large randomized trials evaluated non-inferiority of moderate hypofractionation to conventional fractionation: CHHiP, RTOG 0415 and PROFIT.

CHHiP study was a randomized controlled phase 3 trial that included 33 216 patients with prostate cancer, clinically staged as T1b-T3aN0M0. Study arms, according to radiation schedules, were the following: 60 Gy given in 20 3- Gy daily fractions, 57 Gy given in 19 3- Gy daily fractions and the control arm of 74 Gy in 37 2-Gy daily fractions. Intensity modulated radiotherapy was used. Whole pelvis radiotherapy was not given. In 97% of patients both neoadjuvant and concomitant antiandrogen therapy was used. Image guided radiotherapy was not performed in 53% of patients, equally in each arm of the trial. Median follow up was 64 months and biochemical or clinical failure (BCF) was set up as the study outcome. At five years, the proportion of patients that were BCF free was 90.6% for 60 Gy in 20 fractions, 85.9% for 57 Gy in 19 fractions and 88.3% for standard fractionation- 74 Gy in 37 fractions. Therefore 60 Gy was proven to be non-inferior to 74 Gy. When compared to the control arm, 57 Gy could not be claimed non-inferior. Late toxicity was not significantly different between the treatment arms. Frequencies of bladder and bowel grade ≥ 2 adverse reactions were 11.7% and 11.9% respectively for 60 Gy group, 6.6% and 11.3% for 57 Gy group and 9.1% and 13.7% for the control group (17).

In RTOG 0415 trial 1115 low-risk prostate cancer patients were randomized to receive 73.8 Gy given in 41 daily fractions of 1.8 Gy during 8.2 weeks, which was conventional regimen (C-RT, CF), or 70 Gy given in 28 fractions of 2.5 Gy through 5.6 weeks (hypofractionated radiotherapy, H-RT). The trial was designed to establish if the 5-year disease-free survival (DFS) of patients who underwent hypofractionated radiotherapy would not be worse than 5-year DFS of conventionally irradiated patients by more than 7.65% (HR < 1.52). Androgen suppression was not allowed, except in case of prostate cancer recurrence as a salvage treatment. Median follow up was 5.8 years. The estimated 5-year (DFS) was 86.3% in the H-RT arm and 85.3% in the C-RT arm. The DFS HR was 0.85, therefore meeting predefined non-inferiority criterion (p < 0.001). No significant difference in acute toxicities was observed between the arms. Patients in H-RT arm of the trial had more often late grade 2 and 3 genitourinary and gastrointestinal adverse events (HR 1.31 to 1.59) (18).

1206 intermediate-risk prostate cancer patients were enrolled in PROFIT trial. Patients allocated in hypofractionated arm of the trial received 60 Gy in 20 daily fractions; overall treatment time was 4 weeks. Patients in the control arm (conventional RT) received 78 Gy in 39 daily fractions. Patients were not permitted to receive androgen deprivation treatment. Biochemical-clinical failure (BCF) was set up as the primary outcome. It included PSA failure (defined as
nadir PSA value + 2), hormonal treatment, clinical relapse (local or distant) or prostate cancer death. No difference has been observed between the arms in 5-year BCF after a median follow up of 6 years (85%). No significant differences have been reported in overall survival or late grade ≥ 3 genitourinary and gastrointestinal toxicity (19).

Even though these three trials enrolled different risk group patients and the use of androgen deprivation therapy among them varied, all of them met their primary aim to prove non-inferiority of moderate hypofractionation to conventional fractionation. Regarding late toxicity, no difference between the two arms was reported in CHHiP and PROFIT trial, while in RTOG trial late toxicity was more common with MF.

Four superiority randomized trials failed to demonstrate any difference in efficacy, including metastasis-free, cancer-specific survival and overall survival (14).

HYPRO trial included 820 patients with localized T1b-4 prostate cancer. Their PSA level had to be below 60 ng/ml and they were staged as intermediate or high-risk. Patients were randomized to receive either hypofractionated or conventionally fractionated radiotherapy. Hypofractionated regimen (HF) consisted of 64.6 Gy given in 19 fractions, 3.4 Gy each, three times a week. Conventional regimen (CF) was 78 Gy in 39 daily fractions over 8 weeks. Equivalent total dose for hypofractionation was 90.4 Gy (calculated using α/β ratio of 1.5 Gy for prostate cancer), which was considerably higher than 78 Gy given in the control group in conventional manner. Concomitant hormonal therapy was given to 67% of patients; its median duration was 32 months. Relapse-free survival (RFS) was the study’s primary endpoint.

After a median follow-up of 60 months, patients allocated to hypofractionation arm had a 5-year RFS of 80.5% and patients irradiated conventionally had a 5-year RFS of 77.1%. There was no difference in frequency of G ≥2 gastrointestinal or genitourinary toxicity 3 months upon radiotherapy. However, 120 days upon treatment, G ≥2 acute gastrointestinal toxicity was more frequent after hypofractionation: 42% vs. 31.2%. Regarding late toxicity, for grade 2 gastrointestinal and genitourinary adverse events, treatment arms could not be declared non-inferior. Cumulative G ≥3 late genitourinary toxicity was also significantly higher after HF: 19.0% vs. 12.9% (p=0.021). No significant difference between treatment arms has been observed when it comes to cumulative G ≥3 late gastrointestinal toxicity: it was 3.3% for HF, 2.6% for CF (p =0.55). There were no treatment-related deaths (20, 21, 22).

In the trial published by Arcangeli, 168 high-risk prostate cancer patients underwent conventional or hypofractionated radiotherapy (HF). Conventional fractionation was 80 Gy, with 2 Gy daily fractions, 5 days a week. Hypofractionated treatment consisted of 62 Gy with 3.1 Gy per fraction; overall treatment time was 5 weeks. All patients received hormonal therapy for 9 months. After 70 months of follow up, isoeffectiveness of the 2 fractionation schedules was confirmed. In a subset of patients whose initial PSA levels were ≤ 20 ng/ml, certain benefit in favor of HF could not be excluded (23).

Similarly, in trials published by Hoffman and Pollack comparing MH with CF, no significant difference in five- year biochemical recurrence free (BRF) survival was observed (14, 24, 25, 26).

Randomized trials comparing conventional fractionation with moderate hypofractionation in patients with prostate cancer are summarized in Table 2 (14).

**Extreme hypofractionation**

In extreme hypofractionation (EH) radiotherapy is delivered with fractions higher than 3.4 Gy. They could be applied daily, weekly or on alternate days. Total dose is up to 35–50 Gy. Delivery of a large radiation dose in small number of bigger fractions takes the advantage of the prostate’s α/β ratio estimated to be about 1.5 Gy, which is considerably low. It is also referred to as stereotactic body radiation therapy (SBRT). Modern image-guided techniques allow deliverance of brachytherapy-like doses with sparing of adjacent tissues. It has been evaluated in a number of phase I and II trials on small groups of low-risk patients.

Two trials with longer follow-up are those by Katz and Meier (27, 28).

Trial by Katz had a median follow up of 72 months. It recruited 324 low risk patients (PSA <10 ng/ml and Gleason score <7) and 153 intermediate-risk patients, with PSA levels between 10 and 20 ng/ml or Gleason score of 7. 51 patients received androgen deprivation therapy for up to 6 months. Cyber-knife system was used to deliver SBRT with fiducial based image guidance. Applied doses were 35 Gy or 36.25 Gy, given daily in 5 fractions. After bowel preparation all patients 15-20 min prior to treatment received amifos-
### Table 2. Summary table of randomized studies comparing moderate hypofractionation and conventional fractionation in prostate cancer (14)

| Study        | Risk    | Technique | ADT (%) | No. of patients | Fractionation total dose /fractions | Treatment duration | Acute toxicity ≥ grade 2 GI (%) | Acute toxicity ≥ grade 2 GU (%) | Late toxicity ≥ grade 2 GI (%) | Late toxicity ≥ grade 2 GU (%) | 5-year biochemical relapse free survival (%) |
|--------------|---------|-----------|---------|-----------------|-------------------------------------|--------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|--------------------------------------|
| **Superiority randomized studies** |          |           |         |                 |                                     |                    |                                 |                                 |                                 |                                 |                                      |
| Arcangeli (23) | LR/IR 24% HR 76% | CFRT     | 100     | 85              | 80 Gy/40 fractions 2 Gy per fraction | 8 weeks            | 21                              | 40                              | 14                              | 11                              | 92.0                                 |
|              |         |           | 100     | 83              | 62 Gy/20 fractions 3.1 Gy per fraction | 4 weeks            | 35                              | 47                              | 17                              | 16                              | 96.0                                 |
| Hoffman (25)  | LR 28% IR 71% HR 1% | IG- IMRT | 23      | 101             | 75.6 Gy/42 fractions 1.8 Gy per fraction | 8.4 weeks         | 5.1                             |                                  | 16.5                            | 2.6                             | 92.0                                 |
|              |         |           | 25      | 102             | 72 Gy/30 fractions 2.4 Gy per fraction | 6 weeks            |                                  |                                 | 10                              | 15.8                            | 96.0                                 |
| Pollack (26)  | IR 36% HR 64% | IMRT     | 47      | 151             | 76 Gy/38 fractions 2 Gy per fraction | 7.6 weeks         | 47.7                            |                                  | 22.5                            | 13.4                            | 85.0                                 |
|              |         |           | 45      | 152             | 70.2 Gy/26 fractions 2.7 Gy per fraction | 5.2 weeks         | 44.9                            |                                  | 18.1                            | 21.5                            | 81.0                                 |
| HYPRO (20, 21, 22) | IR 27% HR 73% | CFRT     | 67      | 410             | 78 Gy/39 fractions 2 Gy per fraction | 7.8 weeks         | 31.2                            | 57.8                            | 17.7 (G3 + toxicity 2.6%)       | 21.9 (G3 + toxicity 3.3%)       | 77.0                                 |
|              |         |           | 67      | 410             | 64.6 Gy/19 fractions 3.4 Gy per fraction | 6.5 weeks         | 42                              | 60.5                            | 39 (G3 + toxicity 12.9%)        | 41.3 (G3 + toxicity 19%)        | 81.0                                 |
| **Non-inferiority randomised studies** |          |           |         |                 |                                     |                    |                                 |                                 |                                 |                                 |                                      |
| RTOG 0415 (18) | LR      | IMRT 79-80% CFRT 20-21% | 0       | 542             | 73.8 Gy/41 fractions 1.8 Gy per fraction | 8.2 weeks         | 10.3                            | 27.1                            | 14                              | 22.8                            | 85.3                                 |
|              |         |           | 0       | 550             | 70 Gy/28 fractions 2.5 Gy per fraction | 5.6 weeks         | 10.7                            | 27                              | 22.4                            | 29.7                            | 86.3                                 |
| PROFIT (19)   | IR      | IGRT     | 0       | 598             | 78 Gy/39 fractions 2 Gy per fraction | 7.8 weeks         |                                  |                                 | >G3 GI/GU 5.4%                  | >G3 GI/GU 3.5%                  | 79.0                                 |
|              |         |           | 0       | 608             | 60 Gy/20 fractions 3 Gy per fraction | 4 weeks           |                                  |                                 |                                 |                                 | 79.0                                 |
| CHHiP (17)    | LR 15% IR 73% HR 12% | IMRT +/- IGRT | 97      | 1065            | 74 Gy/37 fractions 2 Gy per fraction | 7.4 weeks         | 25                              | 46                              | 13.7                            | 9.2                             | 88.3                                 |
|              |         |           | 97      | 1074            | 60 Gy/20 fractions 3 Gy per fraction | 4 weeks           | 38                              | 49                              | 12                              | 11.7                            | 90.6                                 |
|              |         |           | 97      | 1077            | 57 Gy/19 fractions 3 Gy per fraction | 3.8 weeks         | 38                              | 46                              | 11.2                            | 6.6                             | 85.9                                 |

LR/IR/HR: low/intermediate/high risk prostate cancer, CFRT: conformal radiotherapy, IMRT: intensity-modulated radiotherapy, IGRT: image-guided radiotherapy, ADT: androgen deprivation therapy, GI: gastrointestinal, GU: genitourinary
tine mixed in saline and instilled into the rectum. Primary outcome was biochemical disease-free survival as per Phoenix definition (bDFS). In 14 intermediate and 11 low-risk patients biochemical failures occurred. For patients in low risk group 7-year bDFS was 95.6% and for those in intermediate-risk 89.6% (p < 0.012). Within intermediate-risk group, patients with low intermediate-risk prostate cancer (n=106), namely those with GS 6 and PSA >10 ng/ml or GS 3+4 and PSA <10 ng/ml had a significantly better bDFS compared to patients defined as high intermediate risk (n=47, GS 3+4 and PSA between 10 and 20 ng/ml or GS 4+3). bDFS figures were 93.5% for low intermediate and 79.3% for high intermediate risk group. There was no difference in biochemical disease-free survival among 36.25 Gy and 35 Gy radiation doses (27).

Meier’s trial involved 309 patients in twenty-one center; 172 had a low-risk (ct1b-T2a, GS ≤6 and PSA ≤10 ng/ml, LR) and the remaining 137 intermediate-risk disease (ct1b-T2b with GS = 7 and PSA equal or below 10 ng/ml, or with GS ≤6 and PSA levels less or equal 20 ng/ml, IR). Intermediate risk group patients were further subcategorized, according to Memorial Sloan Kettering (MSK) risk classification system, as favorable or unfavorable. Prescribed dose was 40 Gy in 5 fractions. Patients were treated with Cyber-knife system. During or after SBRT antiandrogen therapy was not permitted. Biochemical failure was defined as “nadir + 2”. Failure was defined as biochemical recurrence or administration of any prostate cancer therapy: salvage, antiandrogen, or systemic.

For the entire patients’ group 5-year overall survival rate was 95.6% and 5-year disease free survival (DFS) rate 97.1%. The 5-year DFS rate was 97.3% for LR patients and 97.1% for IR patients. After a median follow-up of 61 months, 2 LR patients (1.2%) and 2 IR patients (1.5%) experienced G 3 genitourinary adverse events, occurring 11 to 51 months after treatment. No grade 4 or 5 toxicities occurred (28).

King et al. performed a pooled analysis of prospective phase II trials of SBRT from 8 institutions involving 1100 patients with clinically localized prostate cancer. 58% of patients had a low-risk disease, 30% intermediate-risk and 11% of patients were classified as high risk. 14% of patients were given short course of androgen deprivation therapy (ADT). Definition of PSA relapse was nadir PSA +2 ng/ml. Median radiation dose was 36.25 Gy in 4-5 fractions delivered using Cyber knife. 5-year biochemical relapse free survival (bRFS) rate after a median follow up of 36 months was 93% for all patients. For low-risk patients 5-year bRFS rate was 95%, 84% for intermediate-risk patients and 81% for high-risk patients (p < 0.001). 135 patients had a follow-up of minimally 5 years. Their 5-year bRFS rates were 99% if classified as low-risk group and 93% if classified as intermediate-risk group. Addition of ADT did not result in any difference (p = 0.71). In conclusion, these evidences support consideration of SBRT as a therapeutic option in patients with low and intermediate-risk prostate cancer (29).

There are two phase III clinical trials comparing extreme hypofractionation with conventional fractionation: HYPO RT PC and PACE B.

HYPO-RT-PC randomized intermediate risk prostate cancer patients to receive conventional radiotherapy consisting of 78 Gy in 2 Gy daily fractions, 5 days/week or 42.7 Gy in 7 fractions of 6.1 Gy given every other weekday, always including two weekends (HYPO-RT arm). Hypothesis of the trial is to demonstrate 10 percentage points increase (70% to 80%) in freedom from failure for patients in tested arm of the trial (HYPO-RT) 5 years upon the treatment. Failure could be PSA rise or any clinical test showing activity of the disease (30).

PACE B trial includes cohort of patient with low risk prostate cancer (stage T1-T2, ≤ Gleason 3 + 4, PSA ≤ 20 ng/ml) within PACE trial. 874 patients in 38 centers were randomized to SBRT (36.25 Gy given in 5 fractions during 1-2 weeks) or CFMHRT (conventional fractionation, moderate hypofractionation radiotherapy; 78 Gy/39 fractions over 7.5 weeks, or 62 Gy/20 fractions in 4 weeks). Hormonal therapy was not allowed. Acute G ≥2 gastrointestinal (GI) and genitourinary (GU) toxicity was not significantly different between the arms. Frequency of acute G ≥2 GI events was 12.1% in CFMHRT group vs. 10.1% in SBRT group, p=0.368. For acute G ≥2 GU events figures were for CFMHRT 27.2% vs. 23.2% for SBRT, p=0.179. Late toxicity and efficacy data in terms of biochemical or clinical failure are pending (31).

According to NCCN (National Cancer Comprehensive Network) guidelines, extreme hypofractionation with daily doses up to 8 Gy is a treatment option for very low, low, favorable or good-prognostic intermediate NCCN risk group of patients (32).
Brachytherapy

Brachytherapy in prostate cancer can be used as a monotherapy in low and intermediate-risk patients or as a boost to external beam radiotherapy (EBRT) in intermediate and high-risk patients. Depending on the characteristics of the radioactive source, it could be delivered as low dose rate (LDR) or high dose rate (HDR) radiotherapy. The advantage of radiotherapy is that it can be completed in one day. However, it requires anesthesia, most often general, and can lead to acute urinary retention.

LDR brachytherapy uses permanent seeds. The most common sources are Iodine-125, Palladium-103 and Cesium-131 isotopes. Radiation dose is delivered over weeks and months requiring radiation protection for both patients and carers. According to ESTRO/EAU/EORTC recommendations, patients eligible for LDR would be those with stage cT1b-T2a N0, M0; ISUP grade 1 with ≤ 50% of biopsy cores involved with cancer or ISUP grade 2 with ≤ 33% of biopsy cores involved with cancer; an initial PSA level of ≤ 10 ng/ml; a prostate volume of < 50 cm³; an International Prostatic Symptom Score (IPSS) ≤ 12 and maximal flow rate > 15 ml/min on urinary flow test. Absolute contraindications are limited life expectancy, unacceptable operative risks, metastatic disease, ataxia telangiectasia, previous large transurethral resection that precludes seed placement and accurate dosimetry and absence of rectum. (13, 33).

Results of LDR brachytherapy trials are shown in Table 3. (34, 35, 36, 37, 38, 39, 40).

HDR brachytherapy uses radioactive sources that are being placed into the prostate temporarily. Iridium-192 (IR-192) isotope is being introduced through implanted needles or catheters. Radiation dose is delivered in minutes, implantation is temporary and there are no radiation protection issues for patient or carers. Radiation can be delivered in single or multiple fractions. Fractionated HDR brachytherapy as monotherapy can be offered to patients with low- and intermediate-risk prostate cancer. In patients with intermediate and high-risk prostate cancer it can be used as a boost to external beam radiotherapy. Patients with significant urinary outflow symptoms are not candidates for HDR boost (13,41).

A randomized phase-III trial compared external beam radiotherapy (EBRT) alone with EBRT combined with high-dose-rate brachytherapy boost (HDR-BTb) in 218 patients with localized prostate adenocarcinoma. Patients in EBRT arm received a total dose of 55 Gy in 20 daily fractions while patients in HDR-BTb arm received EBRT 35.75 Gy in 13 fractions followed by HDR-BT boost of 2x 8.5 Gy in 24 h. Biochemical/clinical relapse-free survival (RFS) was the primary endpoint. Secondary endpoints were overall survival (OS), urinary and bowel toxicity. After 4 years median time to relapse was 116 months in EBRT + HDR-BTb group, compared to 74 months in EBRT only group. (p = 0.04). In multivariate analysis treatment arm, risk category and ADT were significant covariates for risk of relapse. Differences in OS were not significant. Incidence of severe late urinary and bowel morbidity was similar: the 5 and 7-year incidence for patients with any severe urinary symptom was 26% and 31% for those treated with EBRT + HDR-BTb compared with 26% and 30% for patients in EBRT.

Table 3. Reported outcomes for prostate cancer patients treated with LDR brachytherapy

| Study          | Number of patients | Risk group (%) | Follow up (years) | Biochemical control (%) | CSS | OS  |
|---------------|--------------------|----------------|-------------------|-------------------------|-----|-----|
|               |                    | low intermediate high |                  | Low risk Intermediate risk High risk |     |     |
| Blasko et al (34) | 230               | 45 46 9 | 9 | 87 79 68 | 100 |
| Zelefsky et al (35) | 2693              | 55 40 5 | 8 | 82 70 40 | 83.5 |
| Henry et al (36) | 1298              | 44 33 14 | 10 | 86 77 61 | 98 |
| Morris et al (37) | 1006              | 58 42 0 | 10 | 90 74 98 | 74 |
| Funk et al (38) | 966               | 71 29 0 | 10 | 87 79 97 | 76 |
| Kittel et al (39) | 1989              | 61 30 5 | 10 | 93 78 98 | 89 |
| Fellin et al (40) | 2237              | 66 26 2 | 7 | 68 73 99 | 89 |

CSS: cause specific survival; OS: overall survival
only arm (p = 0.5). The incidence of severe bowel events was 7% and 6%, respectively, at 5 and 7 years (p = 0.8) (42).

Radiotherapy in disease relapse

- salvage radiotherapy

In case of locoregional relapse of the disease, with radiotherapy is possible to achieve cure or at least long-term control, even in previously irradiated patients.

In patients who experience biochemical relapse after radical prostatectomy, who were not irradiated and in whom diagnostic procedures exclude metastatic disease, salvage radiotherapy is indicated. It refers to irradiation of prostate and seminal vesicles bed with doses up to 72 Gy with the addition of hormonal therapy. The role of whole pelvic irradiation is still undetermined. While it is still unclear whether radiotherapy should be given in adjuvant setting in patients with higher risk of locoregional relapse, or as a salvage treatment upon biochemical recurrence, it is undoubtedly proved that early salvage therapy is better than late. Therefore, irradiation should begin when PSA levels reach values between 0.2 and 0.5 ng/ml, or even earlier, with PSA level below 0.2 (43, 44).

Studies of salvage radiotherapy are summarized in Table 4 (13, 44, 45, 46, 47).

Regarding recommended dose, King et al have compared 60 Gy and 70 Gy in 38 and 84 patients with pathologically negative lymph nodes, respectively. Radiotherapy was given beyond 6 months after radical prostatectomy and when PSA was detectable. Whole pelvic RT up to 50 Gy was delivered to 59% of patients. 56% of patients also received 4-months total androgen suppression with LH-RH agonist and oral antiandrogen. Biochemical relapse was defined as detectable PSA level confirmed on repeat testing and rising on subsequent testing. After a median follow-up of >5 years 60 patients experienced biochemical relapse. Median time to relapse was 1.2 years. For patients receiving RT alone the 5-year biochemical relapse free survival (bRFS) rate was 17% vs. 55% (p = 0.016), and for those receiving prostate-bed-only RT it was 23% vs. 66% (p = 0.037) for doses of 60 Gy vs. 70 Gy, respectively. Approximately 2.5% improvement in 5-year bRFS was achieved for each additional Gy. Therefore, a clinically significant dose response from 60 Gy to 70 Gy was observed in the setting of salvage RT after prostatectomy (48).

Disease relapse in pelvic lymph nodes

Patients with lymph node metastasis only have a better prognosis than those with metastasis on other sites with median overall survival and cancer-specific survival of 43 and 61 month, respectively (49).
Subgroup of patients with pelvic lymph nodes metastasis only after radical prostatectomy, regardless of previous prostate bed adjuvant radiotherapy, should be referred to as potentially curable. They should be offered local treatment, with or without hormonal therapy.

In multicenter trial published by Ost et al., 72 prostate cancer patients with ≤3 lymph nodes at the time of recurrence were treated with SBRT, which was defined as a radiotherapy dose of at least 5 Gy per fraction to a biological effective dose of at least 80 Gy to all metastatic sites. The median distant progression-free survival was 21 months and most relapses (68%) occurred in nodal regions. Relapses after pelvic nodal SBRT were located in the pelvis. 5-year distant progression-free survival was 13% (50).

Tran et al. reviewed data of 53 oligorecurrent prostate cancer patients treated with elective nodal radiotherapy (ENRT). 38 patients had a single nodal metastasis located in the pelvis. All patients underwent ENRT between 45 and 50.4 Gy with a boost on positive nodes up to 69 Gy. Concomitant androgen deprivation therapy was administered to all patients for a median time of 6 months. After a median follow-up of 44 months, the 5-year biochemical disease-free and distant progression-free survival (DPFS) rates were 43% and 58%, respectively (51).

In the trial published by Lepinoy, comparison between salvage extended field radiotherapy (s-EFRT) and salvage involved field radiotherapy (s-IFRT) in patients with 18F-fluorocholine (FCh) PET/CT+ nodal oligorecurrences from prostate cancer in terms of times to failure (TTF) and toxicity was made. Of 62 patients with positive lymph nodes only who underwent FCh PET/CT for a rising PSA level after radical prostatectomy or radiotherapy, 35 had s-IFRT and 27 had s-EFRT. 3-year failure rates were 55.3% in the s-IFRT group and 88.3% in the s-EFRT group (p = 0.0094). There was a strong trend toward better outcomes with s-EFRT even after adjusting for concomitant androgen-deprivation therapy. After a median follow-up of 41.8 months (range 5.9-108.1 months), no differences were observed in acute or late gastrointestinal and genitourINARY toxicities of grade 2 or more between the two groups (52).

These data suggest that in subgroup of patients with pelvic nodal relapse only, extended field radiotherapy should be treatment of choice rather than stereotactic irradiation of affected lymph nodes.

Discussion

There is a robust data available proving efficacy of radiotherapy in prostate cancer in different stages of the disease. Introduction of ISUP grade system, further stratification of risk groups and different study endpoints, as well as their definition, makes the interpretation and comparison of those trials truly challenging.

Dose escalation led to better biochemical control of the disease, which has in some trials translated into better survival, especially in patients in higher risk groups. The impact of dose escalation on acute and late treatment toxicities is quite inconsistent across the published trials but, in general, late gastrointestinal toxicity is more frequently observed in patients receiving higher radiation doses. According to NCCN guidelines, doses between 72 and 81 Gy, standard fractionation, are acceptable across the risk groups (32).

Moderate hypofractionation (MH) with daily doses up to 3.4 Gy is convenient due to shorter overall treatment time but could also lead to better disease control regarding low α/β ratio of prostate cancer. It has proven its non-inferiority in a number of trials in terms of biochemical control of the disease. Again, no consistent conclusions regarding toxicity could be made: no difference between the two arms was reported in CHHiP and PROFIT trial, while in RTOG trial late toxicity was more common with MF (17, 18, 19). As far as superiority trials are concerned, four of those failed to demonstrate any difference in efficacy, including metastasis-free, cancer-specific survival and overall survival between moderate hypofractionation and conventional fractionation. According to ASTRO (American Society for Radiation Oncology), ASCO (American Society of Clinical Oncology) and AUA (American Urological Association) guidelines, in men with low, intermediate and high risk prostate cancer, moderate hypofractionation should be offered with regimens of 60 Gy in 20 fractions and 70 Gy in 28 fractions, since they are supported with the largest evidentiary base. One optimal regimen cannot be determined since most of the multiple fractionation schemes evaluated in clinical trials have not been compared head to head. Though MH has a similar risk of acute and late gastrointestinal and late genitourinary toxicity compared to conventionally fractionated radiotherapy, one should bear in mind limited follow-up beyond five years for most trials (53).
Extreme hypofractionation (EH), also referred as stereotactic body radiation therapy (SBRT), has been evaluated in a number of small phase I and II trials and the results of two-phase III trials comparing it with conventional fractionations are awaiting. According to ASTRO, ASCO and AUA guidelines, it can be offered in men with low-risk prostate cancer who decline active surveillance as an alternative to conventional fractionation. In men with intermediate-risk prostate cancer it may also be offered as an alternative to conventional fractionation, but the task force strongly encourages that these patients be treated as part of a clinical trial or multi-institutional registry. In men with high-risk prostate cancer EH should not be used outside of a clinical trial. Acceptable doses are 35 to 36.25 Gy in 5 fractions of 7 to 7.25 Gy (53).

Brachytherapy presents a valuable treatment option proven in a number of clinical trials, either as a sole modality in low and intermediate risk prostate cancer patients or combined with external beam radiotherapy in both intermediate and high-risk patients. Nevertheless, after summarizing evidence from recent randomized trials, American Brachytherapy Society Task Group finds out that combination of brachytherapy and external beam therapy may become the standard of care for patients with high-risk prostate cancer (54). Unfortunately, its availability can be limited. When opting for brachytherapy in order to keep its toxicity to a minimum, patient selection seems to be crucial (33).

In case of disease relapse, if it is locoregional, radiotherapy can still be a curative method. When it comes to biochemical relapse in previously unirradiated patients, radiotherapy of the prostate and seminal vesicles bed should be delivered early, before PSA reaches the level of 0.5 ng/ml. Patients with metastases in pelvic lymph nodes only should be treated with curative intent with a whole pelvis irradiation instead of an involved field.

References

1. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR; CaPSURE. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003 Dec;170(6 Pt 2):S21-5; discussion S26-7.

2. Egevad L, Delahunt B, Srigley JR, Samarutanga H. International Society of Urological Pathology (ISUP) grading of prostate cancer - An ISUP consensus on contemporary grading. APMIS. 2016 Jun;124(6):433-5.

3. Epstein JI, Zelefsky MJ, Stojberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016 Mar;69(3):428-35.

4. Deannaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014 Apr;15(4):464-73.

5. Beckendorf V, Guerif S, Le Prise E, Cosset JM, Bougnoux A, Chauvet B, et al. 70 Gy versus 80 Gy in localised prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011 Jul;80(4):1056-63.

6. Peeters ST, Heemersen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006 May 1;24(13):1990-6.

7. Heemsen WD, Al-Mamgani A, Slot A, Dielwart MF, Lebesque JV. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014 Jan;110(1):104-9.

8. Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1310-7.

9. Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG Oncology RTOG 0126 randomized Clinical Trial. JAMA Oncol. 2018 Jun 14;4(6):e180039.

10. Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1405-18.

11. Zan HZ, Li G, Bai S. High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up. J Cancer Res Clin Oncol (2015) 141: 1063-1071.

12. Kalbasi A, Li J, Berman A T, Swisher-McClure S, Smaldone M, Uzzo R G, et al. Dose-escalated irradiation and overall survival in men with non-metastatic prostate cancer. JAMA Oncol 2015;1(7):897-906.

13. EAU Guidelines Office, Arnhem, The Netherlands. http:// uroweb.org/guidelines/compilations-of-all-guidelines/ Accessed on August 13th, 2019.

14. Benjamin LC, Tree AC, Deannaley DP. The Role of Hypofractionated Radiotherapy in Prostate Cancer. Curr Oncol Rep. 2017 Apr;19(4):30.

15. Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, et al. Randomized trial comparing two fractionation...
schedules for patients with localized prostate cancer. J Clin Oncol. 2005;23(25):6132-8.

16. Yoo EH, Botton RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 2011 Dec 1;81(5):1271-8.

17. DeMey C, Syndikus I, Mossop J, Khoo V, Bird R, Bloomfield D et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016;17:1047-60.

18. Lee WR, Dingam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized phase III non-inferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016 Jul 10;34(20):2325-32.

19. Catton CN, Lukka H, Gu C-S, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology 2017 35:17, 1884-1890.

20. Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol. 2015; 16(3):274-83.

21. Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;17(8):1061-1069.

22. Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016 Apr;17(4):464-474.

23. Arcangeli S, Strigari L, Gomellini S, Saracino B, Petrongari GP, Pinnarò P, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1172-8.

24. Kuban DA, Nogueras-Gonzalez, GM, Hamblin L, Lee AK, Choi S, Frank SJ, et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys. 2010 Nov;78(3):S85-S89.

25. Hoffman KE, Voong KR, Pugh TJ, Skinner H, Levy LB, Taktar V, et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1074-84.

26. Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 2013 Nov 1;31(31):3860-8.

27. Katz AJ, Kang J. Stereactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol. 2014 Sep 2;4:240.

28. Meier RM, Bloch DA, Cotrutz C, Beckman AC, Henning GT, Woodhouse SA, et al. Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints. Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):296-303.

29. King CR, Freeman D, Kaplan I, Fuller D, Belzicco G, Collins S, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013 Nov;109(2):217-21

30. Phase III study of HYPOfractionated RadioTherapy of intermediate risk localised Prostate Cancer. https://doi.org/10.1186/ISRCTN45905321.

31. Van As NJ, Brand D, Tree A, Ostler Pj, Chu W, Lohlaw A, et al. PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa). Journal of Clinical Oncology 2019 37:7_suppl, 1-1.

32. NCCN Guidelines: Prostate Cancer, (Version 4, 2019, August 19, 2019) at https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed on August 27th, 2019.

33. Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L; ESTRO/EAU Urological Brachytherapy Group; EORTC Radiotherapy Group. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol. 2000 Dec;57(3):315-21.

34. Blasko JC, Grimm PD, Sylvester JE, Radioazamani KR, Hoak D, Cavanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):839-50.

35. Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007 Feb 1;67 (2):327-33.

36. Henry AM, Al-Qaisieh B, Gould K, Bownes P, Smith J, Carey B, et al. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of Leeds 10-year single-centre brachytherapy experience. Int J Radiat Oncol Biol Phys. 2010;76(1):50-6.

37. Morris WJ, Keysel I, Spadinger I, Kwan W, Liu M, McKenzie M, et al. Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer. Cancer. 2013 Apr 15;119(8):1537-46.

38. Funk RK, Davis BJ, Mynderse LA, Wilson TM, Deufel CL, Furutani KM, et al. Permanent Prostate Brachytherapy Monotherapy With I-125 for Low- and Intermediate-Risk Prostate Cancer: Outcome in 966 Patients. Int J Radiat Oncol Biol Phys.2015 Nov 1;93(3) Suppl:E213-214.

39. Kittel JA, Reddy CA, Smith KL, Stephens KL, Tendulkar RD, Ulchaker J, et al. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in
Radiotherapy of prostate cancer: primary radiotherapy and radiotherapy in disease relapse

Katarina Antunac

Low-, Intermediate-, and High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):884-93.

40. Fellin G, Mirri MA, Santoro L, Jereczek-Fossa BA, Divan C, Mussari S, et al. Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions. Br J Radiol. 2016 Sep;89(1065):20150981.

41. Hoskin PJ, Colombo A, Henry A, Niehoff P, Paulsen Hellebust T, Siebert FA, Kovacs G. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol. 2013;107(3):325-32.

42. Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012;103(2):217-22.

43. Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2014 Jun;65(6):1034-43.

44. Bartkowiak D, Thamm R, Bottke D, Siegmann A, Böhmer D, Budach V, et al. Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival. Acta Oncol. 2018 Mar;57(3):362-367.

45. Soto de, Passarelli MN, Daignault S, Sandler HM. Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients. Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1227-32.

46. Stish BJ, Psiansky TM, Harmse WS, Davis BJ, Tzou KS, Choo R, et al. Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. J Clin Oncol. 2016 Nov 10;34(32):3864-3871.

47. Tendulkar RD, Agrawal S, Gao T, Efstratiou JA, Psiansky TM, Michalski JM, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. 2016 Oct 20;34(30):3648-3654.

48. King CR, Spiotto MT. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):23-7.

49. Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffermann J, Trudeau V, et al. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. Eur Urol. 2015 Aug;68(2):325-34.

50. Ost P, Jereczek-Fossa BA, Van As N, Zilli T, Tree A, Henderson D, et al. Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences. Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e115-20.

51. Tran S, Jorcano S, Falco T, Lamanna G, Miralbell R, Zilli T. Oligorecurrent nodal prostate cancer: long-term results of an elective nodal irradiation approach. Am J Clin Oncol. 2018 Oct;41(10):960-962.

52. Lépinoy A, Silva YE, Martin E, Bertaut A, Quivrin M, Aubignant L, et al. Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):40-48.

53. Scott C, Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, et al. Hypofractionated radiation therapy for localized prostate cancer: An ASTRO, ASCO, and AUA evidence-based guideline. Journal of Clinical Oncology 2018 36:34, 3411-3430.

54. Spratt DE, Soni PD, McLaughlin PW, Merrick GS, Stock RG, Blasko JC, et al. American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer. Brachytherapy. 2017 Jan - Feb;16(1):1-12.

---

Sažetak

RADIOTHERAPIJA RAKA PROSTATE: PRIMARNA RADIOTHERAPIJA I RADIOTHERAPIJA U POVRATU BOLESTI

K. Antunac

Radioterapija predstavlja jedan od osnovnih modaliteta liječenja bolesnika s rakom prostate u gotovo svim stadijima bolesti. Može se koristiti kao vanjsko zračenje, kao brahiterapija (unutarnje zračenje) ili kombinacija ove dvije metode. Više doze zračenja su dokazano učinkovitije od nizićih a umjereno hipofrakcionirano zračenje dozama od 3,4 Gy po frakciji je jednako učinkovito kao i zračenje standardnim frakcioniranjem od 1,8–2 Gy po frakciji. Stereotaksisko zračenje dozama od 3,4 do 7,25 Gy po frakciji predstavlja vrijednu opciju kod određenih podskupina bolesnika. U slučaju lokoregionalnog povratka bolesti, zračenje se može provoditi s ciljem izloženja bolesnika.

Ključne riječi: rak prostate, radioterapija, brahiterapija, hipofrakcioniranje, stereotaksisko zračenje, spasonosna radiotherapija